Please find attached.
APLLTD · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Alembic Pharmaceuticals reported Q4 FY '26 revenue of INR 1,838 crores (up 4% YoY) with EBITDA before R&D at INR 455 crores (up 8% YoY) and margins improving to 25% from 24% a year ago. Full year FY '26 revenue grew ~10% with EBITDA at 25% of revenue and PAT of INR 675 crores (up 16%). Management guided FY '27 for low double-digit top-line growth, R&D spend of INR 750-800 crores, and capex of INR 300-350 crores. The U.S. branded business (Pivya launched February 2026) caused ~100-150 bps margin drag but management expects core business operating leverage to offset this by year-end. Management specifically stated they expect margin improvement in FY '27 and a return to 20% EBITDA margins over a 2-3 year period. Key new launches (6 in Q4), improving capacity utilization at F2/F3 facilities, and focus on Day 1 and complex products support the outlook.
The call signals improving margins ahead as facility utilization improves and the U.S. branded business reaches breakeven. Management's explicit margin improvement guidance for FY '27 and medium-term 20% EBITDA target is a positive signal for shareholders, though near-term R&D intensity and branded business drag remain headwinds.